Urologix, Inc. engages in the development, manufacture, and marketing of minimally invasive medical products for the treatment of urological disorders. The company develops and offers nonsurgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia (BPH), a noncancerous disease in which the prostate enlarges and constricts the urethra causing adverse changes in urinary voiding patterns. Its products include the CoolWave, Targis, and Prostatron control units, as well as the cooled ThermoCath, Targis, and Prostaprobe catheter families that utilize cooled ThermoTherapy targeted microwave energy...